@article{f243289a73924f4faeb0a8f068541700,
title = "Improving myelopathy diagnosis now and into the future",
keywords = "Differential diagnosis, Misdiagnosis, Myelitis, Myelopathy, Spinal cord",
author = "Laura Cacciaguerra and Flanagan, {Eoin P.}",
note = "Funding Information: Laura Cacciaguerra received speaker and consultant honoraria from ACCMED, Roche, BMS Celgene, and Sanofi and travel support for conference attendance from Merck Serono. Eoin P. Flanagan has served on advisory boards for Alexion, Genentech and Horizon Therapeutics. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr. Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr. Flanagan has received funding from the NIH (R01NS113828). Dr. Flanagan is a member of the medical advisory board of the MOG project. Dr. Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. ",
year = "2022",
month = nov,
day = "15",
doi = "10.1016/j.jns.2022.120424",
language = "English (US)",
volume = "442",
journal = "Journal of the neurological sciences",
issn = "0022-510X",
publisher = "Elsevier",
}